Bristol-Myers Squibb Company (BMY) Latest Stock News
Get the latest Bristol-Myers Squibb Company (BMY) stock news and headlines to help you in your trading and investing decisions.
Bristol Myers Squibb (BMY) Stock Declines While Market …
3 days ago · The latest trading session saw Bristol Myers Squibb (BMY) ending at $56.59, denoting a -0.35% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of 1 ...
Bristol Myers Squibb Co. - MarketWatch
4 days ago · BMY | Complete Bristol Myers Squibb Co. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Bristol-Myers Squibb Company (BMY) - Yahoo Finance
Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing.
BMY - Bristol-Myers Squibb Co News - Morningstar
Dec 31, 2024 · Read about Bristol-Myers Squibb Co (BMY:XNYS) stock and today's latest news and financial updates.
Bristol-Myers Squibb Stock: 2H24 Culminates In Opdivo 'Subcu' …
Dec 30, 2024 · Perhaps the best news of the year for BMY came when rival Pharma AbbVie reported that its schizophrenia drug emraclidine, acquired as part of its $8.7bn buyout of Cerevel Therapeutics, failed to ...
Pharmaceutical press releases & news - Bristol Myers Squibb
4 days ago · Explore Bristol Myers Squibb's latest press releases to learn more about our company, our medicines, research innovation and other news as we work to support patients fighting serious disease.
BMY - | Stock Price & Latest News | Reuters
3 days ago · Get Bristol-Myers Squibb Co (BMY) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments
Bristol-Myers Squibb Company (BMY) Latest Stock News - Seeking Alpha
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
Bristol Myers Squibb - Bristol Myers Squibb Adds Premier ...
Dec 26, 2023 · PRINCETON, N.J. & SAN DIEGO-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.